Companies › Belief BioMed (Beijing)
2 active drug programs in 2 registered trials: 2 Phase 1; Immunology, Neurology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BBM-D101 AAV-mediated gene addition therapy delivering dystrophin-associated protein complex therap | DMD | Phase 1 | DMD | Jun 2027 |
| BBM-A101 | – | Phase 1 | Knee Osteoarthritis | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07058662 | BBM-D101 | Phase 1 | DMD | Neurology | Jun 2027 |
| NCT07198555 | BBM-A101 | Phase 1 | Knee Osteoarthritis | Immunology | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.